↓ Skip to main content

T cell-NF-κB activation is required for tumor control in vivo

Overview of attention for article published in Journal for Immunotherapy of Cancer, January 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
48 Dimensions

Readers on

mendeley
49 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
T cell-NF-κB activation is required for tumor control in vivo
Published in
Journal for Immunotherapy of Cancer, January 2015
DOI 10.1186/s40425-014-0045-x
Pubmed ID
Authors

Sarah E Barnes, Ying Wang, Luqiu Chen, Luciana L Molinero, Thomas F Gajewski, Cesar Evaristo, Maria-Luisa Alegre

Abstract

T cells have the capacity to eliminate tumors but the signaling pathways by which they do so are incompletely understood. T cell priming requires activation of the transcription factors AP-1, NFAT and NF-κB downstream of the TCR, but whether activation of T cell-NF-κB in vivo is required for tumor control has not been addressed. In humans and mice with progressively growing tumors, the activity of T cell-intrinsic NF-κB is often reduced. However, it is not clear if this is causal for an inability to reject transformed cells, or if it is a consequence of tumor growth. T cell-NF-κB is important for T cell survival and effector differentiation and plays an important role in enabling T cells to reject cardiac and islet allografts, suggesting the possibility that it may also be required for tumor elimination. In this study, we tested whether normal T cell-NF-κB activation is necessary for the rejection of tumors whose growth is normally controlled by the immune system.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 2%
Germany 1 2%
Unknown 47 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 19 39%
Researcher 10 20%
Student > Master 5 10%
Student > Bachelor 3 6%
Student > Doctoral Student 3 6%
Other 5 10%
Unknown 4 8%
Readers by discipline Count As %
Immunology and Microbiology 18 37%
Agricultural and Biological Sciences 14 29%
Biochemistry, Genetics and Molecular Biology 6 12%
Medicine and Dentistry 4 8%
Psychology 1 2%
Other 1 2%
Unknown 5 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2015.
All research outputs
#11,475,656
of 18,255,134 outputs
Outputs from Journal for Immunotherapy of Cancer
#1,530
of 1,923 outputs
Outputs of similar age
#154,803
of 299,951 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#18
of 21 outputs
Altmetric has tracked 18,255,134 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.7. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 299,951 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.